Navigation Links
Neurologix Announces Publication of Landmark Gene Therapy Study,Demonstrating Safety and Statistically Significant Improvement in,Patients With Advanced Parkinson's Disease

roughout the duration of the 12-month study, or in the subsequent two years since the study formally ended.

About Neurologix

Neurologix, Inc. is a development-stage company engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease, epilepsy and other neurodegenerative and metabolic disorders. Neurologix's core technology, "NLX," is currently in the clinical development stages, having recently been tested in a company-sponsored Phase I human clinical trial to treat Parkinson's disease.

Cautionary Statement Regarding Forward-looking Statements

This news release includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any futu
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:
(Date:11/6/2009)..., NEW YORK, Nov. 6 Keryx...ld a conference call on Tuesday, November 10, 2009...9 financial results and business outlook for the r...ficer of the Company, will host the call. Keryx w... in a press release to be issued prior to the call...
(Date:11/6/2009)..., HOUSTON, Nov. 6 Cybero...he company will report financial results for the s... year ending April 30, 2010 on Wednesday, November...t a conference call to discuss those results on Th...Fiscal Year 2010 Second Quarter Results Conference...
(Date:11/6/2009)..., SAN DIEGO, Nov. 6 NexBio Inc., i... Disease Control and Prevention (CDC), St. Louis U...ced today the publication of two articles in the p...d studies suggest that DAS181 (Fludase ® ) ma...ent and prevention of the Pandemic Influenza A(H1N...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 1Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 2Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 3Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 4Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 5Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 6Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 7Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 8Enbrel 28R 29 28etanercept 29 Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 59669 9Rotary Declares World Polio Day 59667 1U M to Host Two Part Tweet Chat on H1N1 Swine Flu Oct 22 59665 1
...an Francisco Bay research seeks couples ...N, Calif., Sept. 28 Reproductive Science Center,o...ViaCell, Inc., has been,awarded a research grant t..., an investigational product intended to broaden r... thawing of human eggs (oocytes).,RSC,s IVF and Me...
... Screen / Triage Test for Human,Appendicitis, Adva...Showing Sensitivity Level of...rma,Inc. (Nasdaq: APPY ) an emerging bio-pharmace...el drugs and diagnostics for animals and humans, t...FDA multi-hospital study using,its AppyScore(TM) h...
Other Medicine Technology:Bay Area Women Sought for Egg Freezing Study 2AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 2AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 3AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 4AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 5AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 6AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 7AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 8AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study 9
(Date:11/7/2009)...re/ -- The American Medical Association (AMA) prou...e Family Violence Prevention Fund, with the Citati...ual policy-making meeting. The Citation for Disti...e of Delegates bestows on a non-physician. ,,...81209/AMALOGO ) ,, "Ms. James has worked self...
(Date:11/7/2009)...responsibility to vigorously oppose abortion in he...ASHINGTON, Nov. 7 Am...the following statement on the news that Cardinal ...Affordable Health Care for America Act (H.R. 3962)...for abortion is voted upon. ,, "Our Catholic b...
(Date:11/7/2009)...l rebel, expert says , , SATURDAY, Nov. 7 ...e badly if their parents expect them to, a new U.S... simply being realistic might actually contribute ...a psychology professor at Wake Forest University a...ws release. "Negative expectations on the part of ...
(Date:11/7/2009)...from Greensations fights pain and increases circul...ThermaFeet targets foot pain and soreness with a s...alnut, Goldenseal, Vitamin C and Alpha Lipoic Acid...WEB) November 7, 2009 -- A new foot spray from Gre...th the power of hot peppers and caffeine. The main...
(Date:11/6/2009)...ia & Lymphoma Society (LLS) will again be part...ich in its first two campaigns this past spring an... LLS,s blood cancer research funding and patient e...ign, taking place from November 12th to 15th, Gap ...s participants can use (in-store only) at all Ga...
Breaking Medicine News(10 mins):Health News:AMA Honors Family Violence Prevention Expert 2Health News:Statement Regarding Cardinal Rigali's Memo Protecting the 'Status Quo' On Life 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:Hot Peppers and Caffeine Relieve Painful Feet, Toe Fungus and Foot Odor 2Health News:Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer 2
... -- Researchers have discovered a novel molecular ...biliary cirrhosis, a disease that mainly affects w...iary cirrhosis has no known cause. , The finding,...England Journal of Medicine . , "Now that we bet...
...7 The Partnership to Fight Chronic Disease (PFCD)...ax Baucus (D-Mont.), and Ranking Member Sen. Charl...nd management of chronic diseases and their risk f...rship noted however, in comments submitted Friday ...
... 27 WellPoint, Inc. (NYSE: WLP ) announced toda...t the following conferences: , , , , Ci...t 10:15 a.m. Eastern Daylight Time ("EDT"); and ,...ested parties are invited to listen to webcasts of...
...c gains in both short-term and long-term survival ...s) -- Over the past 15 years, the average survival...ncer has increased dramatically, new research indi...rage patient would have survived about 14 months p...
...s Fund Summer Lunch Program aims to increase parti... , , MINNEAPOLIS, May 27 The Minnesota Vikings, H...land today announced the official launch of the ...Minnesota children this summer. The Vikings have p...
... Making sure you look good in your swimwear this s...ym. Here,s more on the importance of also making ... , Listen to this report from Procter & Gamble...s and photos for free and unrestricted use at h...
Other Medicine News:Health News:Mayo researchers help discover genetic cause for primary biliary cirrhosis 2Health News:Mayo researchers help discover genetic cause for primary biliary cirrhosis 3Health News:Coalition Commends Senators Baucus, Grassley for Including Prevention, Wellness of Chronic Disease in Recent Paper on Coverage Policy Options 2Health News:WellPoint Announces Appearances at Upcoming Conferences 2Health News:More Living Longer With Advanced Colon Cancer 2Health News:More Living Longer With Advanced Colon Cancer 3Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 2Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 3Health News:Minnesota Vikings, Hunger Solutions Minnesota and Second Harvest Heartland to Help Secure 200,000 Meals for Hungry Minnesota Children This Summer 4
DePuy ScanMed Tourniquet System
...en designed so the surgeon can gently retract and ...ative surface. It allows the surgeon to perform th...is controlled versatility will give the surgical a... broaden the range of procedures the surgeon can p...
...onary new addition to the Hall® Surgical line ...ery System is the first and only software controll...ket. It is a full-function orthopedic power system... large bone, small bone, arthroscopy and trauma ap...
MiniView 6800 Digital Mobile C-Arm
Medicine Products: